Epitope classification and RBD binding properties of neutralizing antibodies against SARS-CoV-2 variants of concern
Author:
Deshpande Ashlesha, Harris Bethany D., Martinez-Sobrido Luis, Kobie James J., Walter Mark R.ORCID
Abstract
AbstractSevere acute respiratory syndrome coronavirus-2 (SAR-CoV-2) causes coronavirus disease 2019 (COVID19) that is responsible for short and long-term disease, as well as death, in susceptible hosts. The receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) protein binds to cell surface angiotensin converting enzyme type-II (ACE2) to initiate viral attachment and ultimately viral pathogenesis. The SARS-CoV-2 S RBD is a major target of neutralizing antibodies (NAbs) that block RBD - ACE2 interactions. In this report, NAb-RBD binding epitopes in the protein databank were classified as C1, C1D, C2, C3, or C4, using a RBD binding profile (BP), based on NAb-specific RBD buried surface area and used to predict the binding epitopes of a series of uncharacterized NAbs. Naturally occurring SARS-CoV-2 RBD sequence variation was also quantified to predict NAb binding sensitivities to the RBD-variants. NAb and ACE2 binding studies confirmed the NAb classifications and determined whether the RBD variants enhanced ACE2 binding to promote viral infectivity, and/or disrupted NAb binding to evade the host immune response. Of 9 single RBD mutants evaluated, K417T, E484K, and N501Y disrupted binding of 65% of the NAbs evaluated, consistent with the assignment of the SARS-CoV-2 P.1 Japan/Brazil strain as a variant of concern (VoC). RBD variants E484K and N501Y exhibited ACE2 binding equivalent to a Wuhan-1 reference SARS-CoV-2 RBD. While slightly less disruptive to NAb binding, L452R enhanced ACE2 binding affinity. Thus, the L452R mutant, associated with the SARS-CoV-2 California VoC (B.1.427/B.1.429-California), has evolved to enhance ACE2 binding, while simultaneously disrupting C1 and C2 NAb classes. The analysis also identified a non-overlapping antibody pair (1213H7 and 1215D1) that bound to all SARS-CoV-2 RBD variants evaluated, representing an excellent therapeutic option for treatment of SARS-CoV-2 WT and VoC strains.
Publisher
Cold Spring Harbor Laboratory
Reference43 articles.
1. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals;Immunity,2020 2. McAndrews, K. M. , Dowlatshahi, D. P. , Dai, J. , Becker, L. M. , Hensel, J. , Snowden, L. M. , Leveille, J. M. , Brunner, M. R. , Holden, K. W. , Hopkins, N. S. , Harris, A. M. , Kumpati, J. , Whitt, M. A. , Lee, J. J. , Ostrosky-Zeichner, L. L. , Papanna, R. , LeBleu, V. S. , Allison, J. P. , and Kalluri, R. (2020) Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI insight 5 3. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates 4. Hansen, J. , Baum, A. , Pascal, K. E. , Russo, V. , Giordano, S. , Wloga, E. , Fulton, B. O. , Yan, Y. , Koon, K. , Patel, K. , Chung, K. M. , Hermann, A. , Ullman, E. , Cruz, J. , Rafique, A. , Huang, T. , Fairhurst, J. , Libertiny, C. , Malbec, M. , Lee, W. Y. , Welsh, R. , Farr, G. , Pennington, S. , Deshpande, D. , Cheng, J. , Watty, A. , Bouffard, P. , Babb, R. , Levenkova, N. , Chen, C. , Zhang, B. , Romero Hernandez, A. , Saotome, K. , Zhou, Y. , Franklin, M. , Sivapalasingam, S. , Lye, D. C. , Weston, S. , Logue, J. , Haupt, R. , Frieman, M. , Chen, G. , Olson, W. , Murphy, A. J. , Stahl, N. , Yancopoulos, G. D. , and Kyratsous, C. A. (2020) Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science (New York, N.Y.) 5. Rogers, T. F. , Zhao, F. , Huang, D. , Beutler, N. , Burns, A. , He, W. T. , Limbo, O. , Smith, C. , Song, G. , Woehl, J. , Yang, L. , Abbott, R. K. , Callaghan, S. , Garcia, E. , Hurtado, J. , Parren, M. , Peng, L. , Ramirez, S. , Ricketts, J. , Ricciardi, M. J. , Rawlings, S. A. , Wu, N. C. , Yuan, M. , Smith, D. M. , Nemazee, D. , Teijaro, J. R. , Voss, J. E. , Wilson, I. A. , Andrabi, R. , Briney, B. , Landais, E. , Sok, D. , Jardine, J. G. , and Burton, D. R. (2020) Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science (New York, N.Y.)
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|